Solid lipid nanoparticles: Influence of composition, fabrication methods and problems, in vitro drug release and intranasal administration provide to access olfactory bulb pathway for SLNs

Anil K. Pawar; Laxman G. Hatmode; Harshada R. Khandelwal; Vishal C. Gurumukhi; Shailesh S. Chalikwar

doi:10.30574/gscbps.2021.14.2.0049

Authors

Anil K. Pawar Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
Laxman G. Hatmode Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405
Harshada R. Khandelwal Department of pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405
Vishal C. Gurumukhi Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
Shailesh S. Chalikwar Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.

DOI:

https://doi.org/10.30574/gscbps.2021.14.2.0049

Keywords:

Solid Lipid Nanoparticles, Lipid Nanocarriers, High-Pressure Homogenization (HPH), Lyophilization, Intranasal Delivery, Blood Brain Barrier (BBB)

Abstract

Background: Solid lipid nanoparticles (SLN) have drawn increasing interest in recent years. These nanoparticles are formed from stable or solid lipid mixtures and then stabilized by emulsifiers. As nanoparticles, colloidal particles running in size somewhere in the 10 to 1000 nm range are known. SLN provides fascinating properties, such as minimal scale, massive surface area, high medication piling, correspondence of stages at the interface, and is interested in their ability to enhance drug execution.

Main text: This paper provides a description of the choice of ingredients, the effect of lipids and their structure on the formulation, and the various methods of processing SLN. We explain the characteristics of SLN stability and the possibilities of SLN stabilization by lyophilization in this article. The relation between drug absorption and the complexity of SLN dispersions, which involves the existence of other colloidal structures and the physical state of the lipid, is uncommonly considered. We define the possible problems of SLN preparation and performance on the basis of characterization. First, the nasal route was known to accomplish the avoidance of first-pass hepatic metabolism in order to maximize absolute bioavailability, and secondly, the immediate nose-to-brain pathway to enhance the delivery of brain medicines. SLNs have been designated to increase drug permeability through the blood-brain barrier as a drug delivery device (BBB).

Conclusion: To sum up, this article gives insight SLNs a colloidal drug carrier places together the compensations of polymeric nanoparticles, SLNs have numerous benefits such as easy incorporation of lipid and lipophilic as well as hydrophilic drugs, suitable physical stability, and available at low cost and easy to manufacture. The nasal route was accepted to exploit first its prevention of the hepatic first-pass metabolism to increase the absolute bioavailability, and second, the direct nose-to-brain pathway to enhance the brain drug delivery. SLNs were chosen as a drug delivery system to improve drug permeability across the blood-brain barrier (BBB) and consequently its brain delivery.

Metrics

Metrics Loading ...

References

JE Hulla, SC Sahu, AW Hayes. Nanotechnology: History and future, Journals.Sagepub.Com. 2015; 34: 1318–1321.

C Vauthier, K Bouchemal, Expert Review Methods for the Preparation and Manufacture of Polymeric Nanoparticles, Springer. 2009; 26: 1025–1058.

A.S.-I. journal of pharmaceutics, undefined 1986, Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration, Elsevier. (n.d.).

D Zhang, W Dai, C Duan, L Jia, Y Wang, F Feng, Q Zhang. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system, J. Microencapsul. 2010; 27: 234–241.

A. Beloqui, M. Solinís, A.R.-G.- B. Medicine, undefined 2016, Nanostructured lipid carriers: promising drug delivery systems for future clinics, Elsevier. (n.d.).

Y. Luo, D. Chen, L. Ren, X. Zhao, J. Qin. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability, Elsevier. 2006.

A. Silva, E. González-Mira, M. García, M.E.-C., S.B. undefined 2011, Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound, Elsevier. (n.d.).

C Schwarz, W Mehnert, J Lucks, RM.-J. of controlled release, undefined 1994, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization, Elsevier. (n.d.).

A zur Mühlen, C Schwarz, W.M.-E. journal of pharmaceutics, undefined 1998, Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism, Elsevier. (n.d.).

A. Garud, D. Singh, N. Garud. Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications. 2012.

DZ Hou, CS Xie, KJ Huang, CH Zhu. The production and characteristics of solid lipid nanoparticles (SLNs), Biomaterials. 2003; 24: 1781–1785.

T Hai, X Wan, DG Yu, K Wang, Y Yang, ZP Liu. Electrospun lipid-coated medicated nanocomposites for an improved drug sustained-release profile, Mater. Des. 2016; 162: 70–79.

R Müller, A Dingler, T.S.-H. of, undefined 2000, Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM), Books.Google.Com. (n.d.).

J Liu, J Zhu, Z Du, B Qin. Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles, Drug Dev. Ind. Pharm. 2005; 31: 551–556.

S Weber, A Zimmer, J Pardeike. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art, Eur. J. Pharm. Biopharm. 2014; 86: 7–22.

K. Bhaskar, C. Krishna Mohan, M. Lingam, V. Prabhakar Reddy, V. Venkateswarlu, Y. Madhusudan Rao. Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: In vitro and ex vivo characterization, Drug Dev. Ind. Pharm. 2008; 34: 719–725.

A Garcês, MH Amaral, JM Sousa Lobo, AC Silva. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review, Eur. J. Pharm. Sci. 2018; 112: 159–167.

V Lingayat, N Zarekar, R.S.-N. undefined, Solid lipid nanoparticles: a review, Academia.Edu. (n.d.). 2017.

R. Article, M.K. Sarangi, S. Padhi. SOLID LIPID NANOPARTICLES-A REVIEW, 2016.

S. Kumar, M. Kumar Patel, Sandeep Hanumanaik, K. Ramya Sree. SOLID LIPID NANOPARTICLES; A REVIEW Periodontal treatment View project Application of Nanotechnology in environment and medical View project SOLID LIPID NANOPARTICLES; A REVIEW, Artic. Int. J. Pharm. Sci. Res. 2013; 4: 928–940.

P Blasi, S Giovagnoli, A Schoubben. M.R.-A. drug delivery, undefined 2007, Solid lipid nanoparticles for targeted brain drug delivery, Elsevier. (n.d.). 2020.

P Kaur, K.K.-I. journal of pharmaceutics, undefined 2008, Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits, Elsevier. (n.d.). 2020.

C Pardeshi, P Rajput, V Belgamwar, AT. Pharmaceutica, undefined, Solid lipid based nanocarriers: an overview, Hrcak.Srce.Hr. (n.d.). 2012.

R Müller, W Mehnert, J.L.-E. journal of, undefined 1995, Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery, Pascal-Francis.Inist.Fr. (n.d.). 2020.

P.B.-C.R. in T.D. Carrier, undefined 2004, Physical chemical considerations of lipid-based oral drug delivery—solid lipid nanoparticles, Dl.Begellhouse.Com. (n.d.). 2020.

M Joshi, S Pathak, S Sharma, V.P.-I. journal of, undefined 2008, Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject, Elsevier. (n.d.). 2008.

B. Siekmann, K.W.-P.P. Lett. undefined 1992, Submicron-sized parenteral carrier systems based on solid lipids, (n.d.). 1992.

D Crommelin, HSK J, M Dekker, N York. undefined 1994, Colloidal drug delivery systems, (n.d.). 1994.

S Patel, M Patel, A Patel, M.C.-N.-B, U. Solid lipid nPatel, S., Patel, M., Patel, A., … M.C.-N.-B., 2018, undefined, n.d. Solid lipid nanoparticles for targeted brain drug delivery. Elsevier.anoparticles for targeted brain drug delivery, Elsevier. (n.d.). 2018.

R. Müller, K.P.-I. journal of pharmaceutics, undefined 1998, Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique, Elsevier. (n.d.). 1998.

DJ McClements, J Rao. Food-Grade nanoemulsions: Formulation, fabrication, properties, performance, Biological fate, and Potential Toxicity, Crit. Rev. Food Sci. Nutr. 2011; 51: 285–330.

A Zur Mühlen, WM- Pharmazie. undefined 1998, Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles, Pascal-Francis.Inist.Fr. (n.d.). 1998.

SJ Hur, EA Decker, DJ McClements. Influence of initial emulsifier type on microstructural changes occurring in emulsified lipids during in vitro digestion, Food Chem. 2009; 114: 253–262.

R Cavalli, E Peira, O Caputo, M.G.-I. journal of, undefined 1999, Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins, Elsevier. (n.d.).

N Naseri, H Valizadeh, P Zakeri-Milani. Solid lipid nanoparticles and nanostructured lipid carriers: Structure preparation and application, Adv. Pharm. Bull. 2015; 5: 305–313.

M Durán-Lobato, A Enguix-González, M Fernández-Arévalo, L Martín-Banderas. Statistical analysis of solid lipid nanoparticles produced by high-pressure homogenization: A practical prediction approach, J. Nanoparticle Res. 2013; 15: 1–14.

S Patel, M Patel, A Patel, M.C.-N.-B. undefined 2018, Solid lipid nanoparticles for targeted brain drug delivery, Elsevier. (n.d.). 2018.

V Jenning, A Lippacher. S.G.-J. of microencapsulation, undefined 2002, Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization, Taylor Fr. (n.d.). 2002.

V Yadav, S AlokMahor, S Alok, A.A.-W.J.P. undefined 2014, Solid lipid nanoparticles (sln): formulation by high pressure homogenization, Academia.Edu. (n.d.). 2014.

A. Dingler, S.G.-J. of microencapsulation, undefined 2002, Production of solid lipid nanoparticles (SLN): scaling up feasibilities, Taylor Fr. (n.d.).

EB Souto, S Doktorovova, A Zielinska, AM Silva. Key production parameters for the development of solid lipid nanoparticles by high shear homogenization, Pharm. Dev. Technol. 2019; 24: 1181–1185.

V Jenning, AF Thünemann, SH Gohla, Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids, Int. J. Pharm. 2000; 199: 167–177.

M.G.-P.T. Europe, undefined 1997, Solid Lipid Nanospheres from Warm Micro-Emulsions: Improvements in SLN production for more efficient drug delivery, AVANSTAR Commun. (n.d.). 1977.

L Anurak, G Chansiri, D Peankit, K Somlak. Griseofulvin solid lipid nanoparticles based on microemulsion technique, in: Adv. Mater. Res., Trans Tech Publications Ltd. 2011; 47–50.

D Quintanar-Guerrero, D Tamayo-Esquivel, A Ganem-Quintanar, E Allémann, E Doelker. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres, Eur. J. Pharm. Sci. 2005; 26: 211–218.

JQ Zhang, J Liu, XL Li, BR Jasti. Preparation and Characterization of Solid Lipid Nanoparticles Containing Silibinin, Drug Deliv. 2007; 14: 381–387.

B Sjöström, BB.-I. journal of pharmaceutics, undefined 1992, Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate, Elsevier. (n.d.). 1992.

M Trotta, F Debernardi, O.C.-I. journal of pharmaceutics, undefined 2003, Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique, Elsevier. (n.d.). 2003.

A. de Labouret, O Thioune, H Fessi, JP Devissaguet, F Puisieux. Application of an original process for obtaining colloidal dispersions of some coating polymers. Preparation, characterization, industrial scale-up, Drug Dev. Ind. Pharm. 1995; 21: 229–241.

H Heiati, R Tawashi, NC Phillips, Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization, J. Microencapsul. 1998; 15: 173–184.

M Pikal, S Shah, M Roy, R.P.-I. journal of, undefined 1990, The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure, Elsevier. (n.d.). 1990.

H. Hauser, G.S.-B.A. of Lipid, undefined 1988, Stabilization of small, unilamellar phospholipid vesicles by sucrose during freezing and dehydration, Springer. (n.d.). 1988.

S Vemuri, C Der Yu, JS Degroot, V Wangsatornthnakun, S Venkataram. Effect of sugars on freeze-thaw and lyophilization of liposomes, Drug Dev. Ind. Pharm. 1991; 17: 327–348.

R Lander, W Manger, M Scouloudis, A Ku, C Davis, A Lee, Gaulin Homogenization: A Mechanistic Study, Wiley Online Libr. 2000; 16: 80–85.

H.W.-U. Berlin D. of Pharmacy, undefined Berlin, undefined 1995, Feste lipid-nanopartikel (sln) für die gewebsspezifishe arzneistoffapplikation, (n.d.). 1995.

B. Wei, C. Cai, Z. Jin, Y. Tian, High-pressure homogenization induced degradation of amylopectin in a gelatinized state, Starch - Stärke. 2016; 68: 734–741.

B Wei, C Cai, B Xu, Z Jin, Y Tian. Disruption and molecule degradation of waxy maize starch granules during high pressure homogenization process, Food Chem. 2018; 240: 165–173.

RH Müller, SA Runge, V Ravelli, AF Thünemann, W Mehnert, EB Souto. Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation, Eur. J. Pharm. Biopharm. 2008; 68: 535–544.

A Saupe, KC Gordon, T Rades. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy, Int. J. Pharm. 2006; 314: 56–62.

N Garti, K Sato. Crystallization and polymorphism of fats and fatty acids. 1988.

K Westesen, H.B.-I. journal of pharmaceutics, undefined 1995, Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix?, Elsevier. (n.d.). 1995.

A Puri, K Loomis, B Smith, JH Lee, A Yavlovich, E Heldman, R Blumenthal. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic, Crit. Rev. Ther. Drug Carrier Syst. 2009; 26: 523–580.

V Jenning, M Schäfer-Korting. S.G.-J. of controlled release, undefined 2000, Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties, Elsevier. (n.d.). 2000.

T. Unruh, H. Bunjes, K. Westesen, M.H.J. Koch. Observation of size-dependent melting in lipid nanoparticles, J. Phys. Chem. B. 1999; 103: 10373–10377.

B Siekmann, K.W.-E.J. of P. Sciences, undefined 1994, P287 electron-microscopic characterization of melt-homogenized solid lipid nanoparticles, Elsevier. (n.d.). 1994.

K Westesen, B Siekmann. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles, Int. J. Pharm. 1997; 151: 35–45.

B Siekmann, K.W.-C. and surfaces B. Biointerfaces, undefined 1994, Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles, Elsevier. (n.d.). 1994.

K Westesen, B.S.-I. journal of pharmaceutics, undefined 1997, Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles, Elsevier. (n.d.). 1997.

C Freitas, RH Müller. Stability determination of solid lipid nanoparticles (SLN®) in aqueous dispersion after addition of electrolyte, J. Microencapsul. 1999; 16: 59–71.

C Freitas, R.M.-I. journal of pharmaceutics, undefined 1998, Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLNTM) dispersions, Elsevier. (n.d.). 1998.

H Bunjes, K Westesen. M.K.-I. journal of pharmaceutics, undefined 1996, Crystallization tendency and polymorphic transitions in triglyceride nanoparticles, Elsevier. (n.d.). 1996.

C Freitas, R.M.-E. journal of pharmaceutics and, undefined 1999, Correlation between long-term stability of solid lipid nanoparticles (SLNTM) and crystallinity of the lipid phase, Elsevier. (n.d.). 1999.

H YOSHINO, M.K.-C. and undefined 1983, NII-Electronic Library Service, n.d. 1983.

N.G.-C. and polymorphism of fats and fatty, undefined 1988, Effects of surfactants on crystallization and polymorphic transformation of fats and fatty acids, Marcel Dekker, New York. (n.d.). 1988.

V Venkateswarlu, K Manjunath. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles, J. Control. Release. 2004; 95: 627–638.

M Yasir, UVS Sara. Solid lipid nanoparticles for nose to brain delivery of haloperidol: In vitro drug release and pharmacokinetics evaluation, Acta Pharm. Sin. B. 2014; 4: 454–463.

B Magenheim, MY Levy, S Benita. A new in vitro technique for the evaluation of drug release profile from colloidal carriers - ultrafiltration technique at low pressure, Int. J. Pharm. 1993; 94: 115–123.

S Martins, S Costa-Lima, T Carneiro, A Cordeiro-Da-Silva, EB Souto, DC Ferreira. Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway, Int. J. Pharm. 2012; 430: 216–227.

Y Gupta, A Jain, SK Jain. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain, J. Pharm. Pharmacol. 2007; 59: 935–940.

S Sadegh Malvajerd, A Azadi, Z Izadi, M Kurd, T Dara, M Dibaei, M Sharif Zadeh, H Akbari Javar, M Hamidi. Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation, ACS Chem. Neurosci. 2019; 10: 728–739.